Thymosin alpha-1 benefits and side effects: the evidence

The short answer: thymosin alpha-1 is one of the few peptides with real randomized human trials, and the results depend on the disease. The clearest benefit is in chronic hepatitis B, where a randomized trial found more viral clearance than no treatment. [3] The largest and best-blinded trial, in sepsis, found no survival benefit. [6] COVID-19 results are mixed, and general immune support, anti-aging, and wellness uses have no randomized trial behind them. On side effects, trials consistently describe it as well tolerated, with injection site irritation the most common complaint. [2]

Thymosin alpha-1 (thymalfasin, sold abroad as Zadaxin) is approved in more than 30 countries but has never been FDA approved. [1] This page covers what the trials showed and what they recorded as harms. For the US legal and access picture, see our separate guide, thymosin alpha-1 access: approved abroad, not in the US. This page does not give dosing.

What is thymosin alpha-1, and how is it supposed to work?

Thymosin alpha-1 is a synthetic copy of a 28 amino acid peptide first isolated from the thymus, the gland where T cells mature. It has been used as an immune modifier in hepatitis B and C, as an add-on to vaccines, and in severe infections for about four decades. [1] Reviews describe it as promoting T cell maturation and function and as having been studied in immunocompromised states, cancer, and infections. [2]

It does not kill viruses or bacteria directly. The theory behind every use is that it restores an immune response that is weakened or exhausted. That theory is why it has been tried in such different conditions, and also why the results differ so much between them: helping a weakened immune system is a plausible goal, but whether it changes outcomes has to be tested disease by disease.

Our evidence grade for thymosin alpha-1 is human RCT, the highest grade in our methodology. That grade means randomized trials exist. It does not mean every trial was positive, and the sections below show that several were not.

Does thymosin alpha-1 work for hepatitis B?

This is the use with the strongest single trial and the basis of its approvals abroad.

• The key trial. In a randomized trial of 98 adults with chronic hepatitis B in Taiwan, complete viral response at 18 months was 40.6% in the shorter of two treatment courses, 26.5% in the longer one, and 9.4% in untreated controls. Responses were similar across groups at the end of treatment and accumulated afterward. Blinded biopsies showed less liver inflammation in treated patients, and no significant side effects were observed. None of the responders lost hepatitis B surface antigen. [3]
• The full body of trials. A Cochrane review published in September 2026 pooled 10 randomized trials with 1,349 participants, run between 1991 and 2018 in Bangladesh, China, Italy, Korea, Singapore, and Taiwan. Thymosin alpha-1 may reduce all-cause mortality (risk ratio 0.53, 3 trials) and serious adverse events (risk ratio 0.72, 5 trials), but the reviewers rated the evidence very low certainty for every outcome except serious adverse events, which was low. They found little to no effect on quality of life, an uncertain effect on liver histology, and could not say whether it reduces hepatitis B related illness. [4]

What this means for you: one well-run trial showed a viral response, and the pooled data lean in a favorable direction, but the independent reviewers were not confident the effect is real. Six of the ten trials in that review tested it alongside other treatments, such as interferon or oral antivirals, rather than on its own. [4] If you have hepatitis B, this is a question for a hepatologist, not a reason to seek the peptide.

Does thymosin alpha-1 help in sepsis?

This is where the evidence changed most recently, and where the difference between small and large trials matters most.

• 2013, ETASS. A single-blind trial of 361 ICU patients with severe sepsis at six Chinese hospitals found 28 day mortality of 26.0% with thymosin alpha-1 versus 35.0% with standard care. The relative risk of 0.74 had a confidence interval that crossed no effect (0.54 to 1.02, p = 0.062 in the main analysis). Treated patients had a greater recovery of an immune marker on monocytes. [5]
• 2025, TESTS. A double-blind, placebo-controlled phase 3 trial by the same research group enrolled 1,106 adults with sepsis at 22 centers in China. Mortality at 28 days was 23.4% with thymosin alpha-1 and 24.1% with placebo (hazard ratio 0.99). No secondary or safety outcome differed significantly. A prespecified subgroup analysis suggested possible harm in people under 60 (hazard ratio 1.67) and possible benefit in people with diabetes, but subgroup findings like these only generate hypotheses. The trial was partly funded by the drug's manufacturer, and it still found no benefit. [6]
• 2025 meta-analysis. Pooling 11 randomized trials and 1,927 patients, a meta-analysis by the same group found lower 28 day mortality overall (odds ratio 0.73). Restricted to high quality trials or to multicenter trials, the benefit disappeared, and the authors judged the total sample still too small to settle the question. [7]

The pattern is a familiar one in medicine: smaller and less blinded trials suggested a benefit, and the largest, double-blind trial did not confirm it. The fair summary is that thymosin alpha-1 has not been shown to save lives in sepsis. The inflammation page and the immune function page put this next to other immune-targeted options.

Did thymosin alpha-1 help in COVID-19?

It was widely used for hospitalized COVID-19 patients, so there are many observational studies, and they disagree. [10]

• An early positive report. A retrospective review of 76 patients with severe COVID-19 at two Wuhan hospitals found mortality of 11.1% in treated patients versus 30.0% in untreated ones, along with recovery of T cell counts. [8] Retrospective studies cannot separate the drug's effect from differences in who received it.
• A larger study that matched patients. A retrospective study of 771 critically ill patients at 19 hospitals found lower crude mortality with thymosin alpha-1 (41.3% versus 60.6%). After matching treated and untreated patients on their baseline characteristics, the difference disappeared (51.0% versus 52.9%). [9] This is a useful lesson in how much an unadjusted comparison can mislead.
• The pooled picture. A 2023 meta-analysis of 9 studies with 5,352 patients found no overall effect on mortality (risk ratio 1.03), with very high variation between studies. Subgroups such as older or more severely ill patients looked better, but the authors concluded the results do not support its use in hospitalized adults with COVID-19. [10]
• A small randomized pilot. An open-label US trial of 49 hospitalized patients with low oxygen and low lymphocyte counts found faster CD4 T cell recovery in patients on low-flow oxygen, but no significant difference in clinical recovery. [11]

No large, blinded randomized trial has shown that thymosin alpha-1 improves COVID-19 outcomes.

Does thymosin alpha-1 improve vaccine response?

There is a plausible signal, but from small studies. In a pilot trial in people on hemodialysis, whose immune response to vaccines is often weak, adding thymosin alpha-1 to a pandemic influenza vaccine raised antibody responses at day 21 compared with the vaccine alone, and no adverse event was attributed to it. [12] Antibody levels also fell faster afterward in the groups that received it. This use is part of its approval in some countries as an immune adjuvant, but the evidence is about antibody levels in a specific high-risk group, not about preventing illness in healthy people. [1]

What about immune support, anti-aging, and wellness claims?

This is where marketing and evidence part ways. Online, thymosin alpha-1 is promoted for general immune support, recovery, longevity, chronic fatigue, and long COVID. We found no randomized trial of it in healthy people for any of these purposes. Registered studies of thymalfasin are mostly in cancer, hepatitis B, and critical care. [13]

Two points are worth keeping in mind when you read these claims:

1. The trials were in sick people. Every positive signal above came from people with a specific disease or a measurably weakened immune system. A drug meant to restore immune function in hepatitis or sepsis has no demonstrated effect on a healthy immune system, and "more immune activity" is not automatically better.
2. Even in sick people, the biggest trial was negative. If thymosin alpha-1 could not lower mortality in 1,106 adults with sepsis, a claim that it broadly strengthens immunity in healthy adults is a hypothesis, not a finding. [6]

If you are comparing it with other thymus peptides, see thymosin alpha-1 vs thymulin. Despite the similar name, it is unrelated to thymosin beta-4 and TB-500; see thymosin alpha-1 vs TB-500.

What are the side effects of thymosin alpha-1?

Across decades of use, the safety record of thymosin alpha-1 itself is reassuring. Here is what the trials and reviews recorded.

• Injection site reactions. The most common adverse effects are local irritation, redness, or discomfort where it is injected. [2]
• Effects in combination with interferon. When given with interferon, rare effects such as fever, fatigue, muscle aches, nausea, vomiting, and a low white cell count were reported. [2] These were reported for the combination, so they cannot be pinned on thymosin alpha-1 alone.
• Hepatitis B trials. The 98 patient trial observed no significant side effects. [3] Across five trials, the Cochrane review found fewer serious adverse events with thymosin alpha-1 than with control (risk ratio 0.72), at low certainty, and no excess of non-serious events. [4]
• Sepsis trials. The 2013 trial recorded no serious drug-related adverse event. [5] In the 2025 placebo-controlled trial, no safety outcome differed significantly from placebo. [6]
• COVID-19 pilot. Nine serious adverse events occurred among treated patients, all judged unrelated to the drug. [11]
• Vaccine pilot. No adverse event was attributed to it, and blood counts and chemistry were unaffected. [12]

A 2015 historical review described its safety profile as excellent and virtually devoid of toxicity. [1] The independent Cochrane reviewers were more cautious, rating most hepatitis B outcomes very low certainty because of risk of bias and small numbers. [4] The fair reading is that serious harm from the pharmaceutical product has not shown up in trials, but most trials were small, short, and run in hospitals or clinics.

Who should be cautious with thymosin alpha-1?

Because it is designed to increase immune activity, the main cautions follow from that.

• Known hypersensitivity to the peptide or to any ingredient of the injection is a contraindication. [2]
• Deliberate immunosuppression, such as after an organ transplant, is a contraindication unless the benefit is judged to outweigh the risk, because the drug could work against the medicines that protect the transplant. [2]

Our thymosin alpha-1 page lists the interactions and contraindications in our record. If you take immunosuppressants, steroids, or biologic drugs for an autoimmune condition, talk to the clinician who prescribes them before considering any immune-modulating peptide.

Why do product side effects differ from trial side effects?

The trial safety data describe a regulated pharmaceutical product made to a known standard. That is not what is sold online in the US.

When FDA placed thymosin alpha-1 in 503A Category 2 in 2023, it cited immunogenicity risk, meaning the chance that impurities or altered peptide trigger an immune reaction, and a lack of safety information for compounded product. [14] Products labeled research use only are unapproved drugs when sold for human use, and FDA has said so in warning letters to sellers of such peptides. [16] No regulator verifies those products for identity or purity, so the reassuring trial record does not transfer to them.

Is thymosin alpha-1 legal in the US?

Briefly: it is not FDA approved. FDA placed it in 503A Category 2 in 2023, and FDA's page, current as of April 22, 2026, now lists it as nominated but withdrawn. That takes it out of Category 2, but it is not on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it. [14] [15]

The thymosin alpha-1 regulatory timeline records each dated FDA action, and the thymosin alpha-1 cost page explains why there is no lawful US price. For the full picture, including clinical trials, importation, and oral and nasal forms, read thymosin alpha-1 access: approved abroad, not in the US.

The bottom line

Thymosin alpha-1 earns its human RCT grade, which puts it ahead of most peptides discussed online. But the benefits that hold up are narrow: a viral response in chronic hepatitis B that independent reviewers rate as low confidence, and better antibody responses to a vaccine in a small dialysis study. [4] [12] The sepsis benefit did not survive a large double-blind trial, the COVID-19 benefit did not survive matching and pooling, and the wellness claims were never tested. [6] [10] Its side effect record in trials is mild. Its record as an unregulated product is unknown.

To judge the next study you see, read how to read a peptide study.